RBC: Hopes for Higher Novartis Midterm Sales Growth 'Unrealistic,' Share Reaction 'Overdone'

MT Newswires · 2d ago
01:24 AM EST, 11/20/2026 (MT Newswires) -- RBC Capital Markets believes that expectations for Novartis (NOVN.SW) to issue a higher medium-term sales outlook were "unrealistic" following the Swiss drugmaker's recent investor event. "We believe the -3% reaction to Novartis Meet Management Day was overdone. The +5% mid-term sales growth was in line with our expectations, and hopes for higher were unrealistic, in our view. We thought management executed well during breakout sessions, with focus on Rhapsido (HS/MS), Ianalumab Sjögren's label, abelacimab, and Kisqali," analysts said Thursday. The research firm added that it sees Novartis achieving its 40%-plus core operating income margin target ahead of 2029, provided management executes on its artificial intelligence strategy to cut costs, boost research and development productivity, and speed up development. RBC rates the stock at sector perform, with a price target of 130 francs.